Sign In
Buy ETNB
$14.84
+0 (+0%)
At Close: Jan 29, 2026
89bio to Present at Upcoming Investor Conferences
08:05pm, Monday, 03'rd Aug 2020
SAN FRANCISCO, Aug. 03, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the
13Ds Filings
10:12pm, Friday, 24'th Jul 2020
Activist reports to the SEC from July 16 through July 22, 2020, including positions in Anterix, Inventiva, BeiGene, and two other companies
SAN FRANCISCO, July 13, 2020 -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies.
89bio (ETNB) Jumps: Stock Rises 6.9%
12:26pm, Friday, 10'th Jul 2020
89bio (ETNB) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
89bio Announces Pricing of Upsized Public Offering of Common Stock
01:30am, Wednesday, 08'th Jul 2020
SAN FRANCISCO, July 07, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for
89bio Announces Proposed Public Offering of Common Stock
10:30am, Monday, 06'th Jul 2020
SAN FRANCISCO, July 06, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treat
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced findings from two new interim analyses of data from the Phase 3 H
89bio Appoints Veteran Finance Executive Lota Zoth to Board of Directors
12:00pm, Thursday, 04'th Jun 2020
SAN FRANCISCO, June 04, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treat
Hedge Funds Dumped 89bio, Inc. (ETNB) During The Crash
09:26pm, Wednesday, 27'th May 2020
The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter. Ev
89bio Reports First Quarter 2020 Financial Results and Provides Corporate Update
08:05pm, Wednesday, 13'th May 2020
- Topline results from BIO89-100’s Phase 1b/2a NASH trial are expected in 2H20 - - Announces FDA Clearance of BIO89-100 IND Application for SHTG - SAN FRANCISCO, May 13,.
89bio to Present at Upcoming Investor Conferences
11:30am, Friday, 08'th May 2020
SAN FRANCISCO, May 08, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatm
Zacks Investment Research Downgrades 89bio (NASDAQ:ETNB) to Hold
09:24am, Friday, 24'th Apr 2020
89bio (NASDAQ:ETNB) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to investors on Wednesday, Zacks.com reports. According to Zacks, “89b
22,836 Shares in 89bio (NASDAQ:ETNB) Purchased by Goldman Sachs Group Inc.
10:20am, Tuesday, 21'st Apr 2020
Goldman Sachs Group Inc. acquired a new stake in 89bio (NASDAQ:ETNB) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquir
89bio (NASDAQ:ETNB) Lowered to "Hold" at Zacks Investment Research
06:18am, Monday, 20'th Apr 2020
Zacks Investment Research downgraded shares of 89bio (NASDAQ:ETNB) from a buy rating to a hold rating in a research report sent to investors on Thursday morning, Zacks.com reports. According to Zacks,
89bio (NASDAQ:ETNB) Raised to Buy at Zacks Investment Research
06:06am, Saturday, 18'th Apr 2020
Zacks Investment Research upgraded shares of 89bio (NASDAQ:ETNB) from a hold rating to a buy rating in a research note published on Wednesday, Zacks.com reports. They currently have $26.00 price objec
